美国 · 平台与数据 · Morningstar

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

来源：Morningstar · 美国 8 小时前

Limited (“ HUTCHMED ” or the “Company”) (Nasdaq/AIM:HCM; HKEX:13) today announces that further to its announcement on September 3, 2026 and following the completion of customary…

在 Morningstar 阅读全文登录后可收藏

MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (www.morningstar.com)

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

推荐阅读

Oracle Calls Force Majeure Already?

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

NextDC shares plunge 42% to a near nine-year low after outlook cut

Where Classic Design Meets User Creativity: iCAUR Interprets “Classic Never Fades”

HUTCHMED Announces Closing of KRAS-EGFR-Antibody Conjugate Therapy License to GSK Outside China

分享

推荐阅读

Oracle Calls Force Majeure Already?

Bull markets tend to peak with a whimper, not a bang — but a 15% correction for the S&P 500 may be next

vTv Therapeutics Highlights Cadisegliatin’s Phase III Push to Tackle Type 1 Hypoglycemia

Oil prices end lower in volatile session amid reports of U.S.-Iran diplomacy

NextDC shares plunge 42% to a near nine-year low after outlook cut

Where Classic Design Meets User Creativity: iCAUR Interprets “Classic Never Fades”